UCB half year results 2012: on track for growth
17:00 EDT 1 Aug 2012 | World Pharma News
UCB has announced its consolidated half year 2012 financial results. The first half year was marked by continuous execution and growth of core medicines Cimzia® (certolizumab pegol), Vimpat® (lacosamide) and Neupro® (rotigotine) with combined net..
Original Article: UCB half year results 2012: on track for growth
More From BioPortfolio on "UCB half year results 2012: on track for growth"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
